pembrolizumab,nivolumab,ipilimumab
merck,bms
['kn-564', 'pembro']
 tom - we should instead be asking harder questions about why kn-564 was positive, rather than why all others negative. imho too much enthusiasm for adj pembro, not enough scrutiny. if control arm had all got soc i/o at recurrence then we could assess more pragmatically #esmo22
Urologist & Director of GU Oncology, Peter MacCallum Cancer Centre | Professor, University of Melbourne | Podcasting at GU Cast. Views my own. RT = endorsement